Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Cecilia Calderón, general director at Vigpharma, highlights how the national pharmacovigilance and technovigilance regulations have been evolving during the last five years as well as showcasing the added value of…
Joel Osorio, CEO & Founder Alejandro De La Parra, Co-Founder & Chief Operating Officer Alexa Jeppi, Co-Founder, RegenerAge Beauty & Health Ira Pastor, Board Member …
Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the…
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s…
Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping…
The founder and managing partner of the LatAm-based consultancy Oriundo, Paul Doulton discusses the company’s unique value offering—comprising both industry veterans and global associates to propel business development—while highlighting Mexico…
Gent Hoxha, founder and CEO of lab equipment specialist Aspelab, explains the company’s growth strategy in Mexico, the intricacies of the Mexican medtech market, and how Aspelab’s solutions enhance both…
Victor Casasola, CEO at Canitec, explains the unique business model of his Mexican medical devices success story, offering an integral service to its clients, and showcases the high added value…
Fausto Hernández, CEO at ValidPro, explains the unique business model of the company as well as the high added value of its qualification and validation services; offering integral solution that…
Martin Ferrari del Sel, country manager at Dräger Mexico, explains the importance of enhancing the efficiency ratios in public and private hospitals, considering the shortage of health infrastructure to cover…
Armando Martínez, general manager at Beckman Coulter Mexico, explains the company’s unique business model Coulter, the strong added-value of its broad and innovative healthcare solutions, and how they help improve…
See our Cookie Privacy Policy Here